On November 5, 2015 Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of cancers, reported that Phase 1 data for CUDC-907, Curis’ proprietary dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor will be presented at the 57th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting to be held from Dec. 5-8, 2015 in Orlando, FL (Press release, Curis, NOV 5, 2015, View Source [SID:1234507991]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Principal Investigator of the study, Dr. Anas Younes, Chief of the Lymphoma Service of the Memorial Sloan Kettering Cancer Center in New York City, will present the data in an oral presentation at the meeting.
Additional information on the presentation can be found below and abstracts can be accessed at www.hematology.org.
Oral Presentation
Date/Session Time: Sunday, Dec. 6, 2015, 12:00 PM – 1:30 PM
Session Name: Lymphoma: Chemotherapy, excluding Pre-Clinical Models: NHL – New Drugs
Presentation Title: Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma
Presentation Time: 1:00 PM
Location: Orange County Convention Center, W311